Amicus Therapeutics (NASDAQ: [[ticker:FOLD]]) has named Andrew Mulberg the company’s vice president of regulatory strategy. The pediatric gastroenterologist comes to Cranbury, NJ-based Amicus from the FDA, where he spent six years, most recently as the deputy director of the agency’s Division of Gastroenterology and Inborn Errors Products. Mulberg’s previous roles include posts at Johnson & Johnson (NYSE: [[ticker:JNJ]]).
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
